Technical Analysis for CRXM - Taxus Cardium Pharmaceuticals Group, Inc

Grade Last Price % Change Price Change
grade B 0.1175 17.50% 0.0175
CRXM closed up 17.5 percent on Friday, August 23, 2019, on 7.42 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical CRXM trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
BB Squeeze Started Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Wide Bands Range Expansion 0.00%

Older signals for CRXM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Taxus Cardium Pharmaceuticals Group Inc. is engaged in managing a medical technologies portfolio of equity-based and potential royalty-driven investments. The Company's portfolio includes Angionetics, Inc. (Angionetics); Activation Therapeutics, Inc. (Activation Therapeutics); LifeAgain Insurance Solutions, Inc. (LifeAgain), and a minority investment in Healthy Brands Collective. Angionetics is its subsidiary focused on late-stage clinical development and commercialization of Generx, which is an angiogenic gene therapy product candidate designed for medical revascularization for treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Activation Therapeutics is its subsidiary focused on development and commercialization of Excellagen technology platform, which is a flowable dermal matrix for wound care that has application as a delivery platform for small molecule drugs, proteins and biologics.
Medicine RTT Medical Specialties Clinical Medicine Coronary Artery Disease Gene Therapy Aging Associated Diseases Angina Refractory Angina Revascularization
Is CRXM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 2 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.18
52 Week Low 0.0481
Average Volume 11,560
200-Day Moving Average 0.1087
50-Day Moving Average 0.1123
20-Day Moving Average 0.1007
10-Day Moving Average 0.0987
Average True Range 0.0287
ADX 31.52
+DI 13.2684
-DI 15.5922
Chandelier Exit (Long, 3 ATRs ) 0.0319
Chandelier Exit (Short, 3 ATRs ) 0.1417
Upper Bollinger Band 0.1172
Lower Bollinger Band 0.0842
Percent B (%b) 1.01
BandWidth 32.770606
MACD Line -0.0028
MACD Signal Line -0.005
MACD Histogram 0.0021
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.1445
Resistance 3 (R3) 0.1417 0.1298 0.1400
Resistance 2 (R2) 0.1298 0.1230 0.1313 0.1385
Resistance 1 (R1) 0.1237 0.1187 0.1268 0.1265 0.1370
Pivot Point 0.1118 0.1118 0.1134 0.1133 0.1118
Support 1 (S1) 0.1057 0.1050 0.1088 0.1085 0.0980
Support 2 (S2) 0.0938 0.1007 0.0953 0.0965
Support 3 (S3) 0.0877 0.0938 0.0950
Support 4 (S4) 0.0905